triazoles has been researched along with gsk 1363089 in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Abudayyeh, O; Barzily-Rokni, M; Cooper, ZA; Fisher, DE; Flaherty, KT; Frederick, DT; Garraway, LA; Hahn, WC; Haq, R; Johannessen, CM; Kim, JW; Konieczkowski, DJ; Mesirov, JP; Piris, A; Straussman, R; Tamayo, P; Wargo, JA | 1 |
1 other study(ies) available for triazoles and gsk 1363089
Article | Year |
---|---|
A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors.
Topics: Anilides; Benzimidazoles; Benzocycloheptenes; Cell Line, Tumor; Cells, Cultured; Drug Resistance, Neoplasm; Gene Expression Regulation, Neoplastic; Hepatocyte Growth Factor; Humans; Indoles; MAP Kinase Signaling System; Melanocytes; Melanoma; Microphthalmia-Associated Transcription Factor; NF-kappa B p50 Subunit; Protein Kinase Inhibitors; Proto-Oncogene Proteins B-raf; Proto-Oncogene Proteins c-met; Pyridines; Quinolines; Sulfonamides; Triazoles | 2014 |